Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
Anatole Besarab, Moro O. Salifu, N. Martin Lunde, Vinod Bansal, Steven Fishbane, Frank C. Dougherty, Ulrich BeyerТом:
29
Рік:
2007
Мова:
english
Сторінки:
640
DOI:
10.1016/j.clinthera.2007.04.014
Файл:
PDF, 1017 KB
english, 2007